Open this publication in new window or tab >>Show others...
2026 (English)In: Results in Chemistry, E-ISSN 2211-7156, Vol. 29, article id 103660Article in journal (Refereed) Published
Abstract [en]
The angiotensin II type 2 receptor (AT2R) is part of the renin-angiotensin aldosterone system and modulates central nervous and cardiovascular functions. During various pathological conditions the receptor is upregulated to exert vasodilating, anti-inflammatory, and neuroprotective functions, and therefore represents a promising drug-target. As part of our continuous exploration of agonist and antagonist ligands binding the AT2R, a virtual screening campaign of an in-house library of ∼82,000 compounds were performed. Several pharmacophores from known AT2R ligands were constructed, and in combination with the structural information from an AT2R homology model, we employed a ligand-based approach to identify new ligands with potential for high affinity to the receptor. Fifty hits were identified and tested in vitro, of which ten compounds, representing five scaffold clusters, were found to bind the AT2R. These clusters were validated via a hit expansion, where one of these hits, the first novel class of small molecule AT2R ligand identified in many years, was then selected for further exploration. Through structure-activity relationships studies, one ligand (compound 15a-(S,S)) with sub-micromolar AT2R affinity (Ki = 140 nM) was identified. The ligand also displayed a favorable in vitro profile; low metabolic clearance, good permeability, and fair solubility. Preliminary in vivo pharmacokinetic studies in mice revealed a good systemic exposure of the compound, with an estimated half-life of approximately six hours. The structure of compound 15a-(S,S) differs significantly from all other previously reported AT2R ligands and can serve as a prototype and starting point for further AT2R ligand optimization, and investigation into its agonistic, antagonistic or other functions.
Place, publisher, year, edition, pages
Elsevier, 2026
Keywords
RAAS, Angiotensin II type 2 receptor, Hit identification, Virtual screening, Lead generation
National Category
Medicinal Chemistry Pharmaceutical Sciences Molecular Biology
Identifiers
urn:nbn:se:uu:diva-595328 (URN)10.1016/j.rechem.2026.103660 (DOI)001834803400001 ()
2026-08-132026-08-132026-08-13Bibliographically approved